(Q37701887)

22 August 2017

KIT as a therapeutic target in metastatic melanoma (English)

1 reference

22 August 2017

1 reference

9

1 reference

22 August 2017

Boris C Bastian

17

0 references

Jedd D. Wolchok

3

object named as

Jedd D Wolchok

1 reference

22 August 2017

7

Katherine S Panageas

1 reference

22 August 2017

Richard D Carvajal

1

1 reference

22 August 2017

Cristina R Antonescu

2

1 reference

22 August 2017

Paul B Chapman

4

1 reference

22 August 2017

Ruth-Ann Roman

5

1 reference

22 August 2017

Jerrold Teitcher

6

1 reference

22 August 2017

Klaus J Busam

8

1 reference

22 August 2017

Jose Lutzky

10

1 reference

22 August 2017

Anna C Pavlick

11

1 reference

22 August 2017

Anne Fusco

12

1 reference

22 August 2017

Lauren Cane

13

1 reference

22 August 2017

Naoko Takebe

14

1 reference

22 August 2017

Swapna Vemula

15

1 reference

22 August 2017

Nancy Bouvier

16

1 reference

22 August 2017

Gary K Schwartz

18

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 June 2011

1 reference

The Journal of the American Medical Association

22 August 2017

1 reference

22 August 2017

305

1 reference

22 August 2017

22

1 reference

22 August 2017

2327-2334

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

23 August 2017

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Imatinib targeting of KIT-mutant oncoprotein in melanoma.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Phase II trial of imatinib mesylate in patients with metastatic melanoma.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Major response to imatinib mesylate in KIT-mutated melanoma.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Somatic activation of KIT in distinct subtypes of melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Distinct sets of genetic alterations in melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Lack of clinical efficacy of imatinib in metastatic melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

The role of Kit-ligand in melanocyte development and epidermal homeostasis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Cancer. Addiction to oncogenes--the Achilles heal of cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Mutations of the BRAF gene in human cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Signaling and transcriptional regulation in the neural crest-derived melanocyte lineage: interactions between KIT and MITF

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Toxicity and response criteria of the Eastern Cooperative Oncology Group

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Optimal two-stage designs for phase II clinical trials

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

KIT gene mutations and copy number in melanoma subtypes

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Melanoma incidence and mortality among US whites, 1969-1999.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986039

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 September 2018

1 reference

12 December 2020

Loss of c-kit expression in cultured melanoma cells

1 reference

12 December 2020

KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells

1 reference

12 December 2020

Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression

1 reference

12 December 2020

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy

1 reference

12 December 2020

MC1R germline variants confer risk for BRAF-mutant melanoma

1 reference

12 December 2020

Identifiers

DOI

10.1001/JAMA.2011.746

1 reference

22 August 2017

1 reference

22 August 2017

PubMed publication ID

21642685

1 reference